LONDON (ShareCast) - (Sharecast News) - Physiomics announced its participation in the American Association for Cancer Research (AACR) annual meeting on Friday, being held in Orlando on 14-19 April.
The AIM-traded oncology consultancy said it would give an oral presentation titled 'development and validation of a quantitative systems pharmacology model for prediction of preclinical efficacy of PARP inhibitors rucaparib and talazoparib combined with the ATR inhibitor gartisertib'.

It said the presentation was co-authored by client Merck KGaA, and was focussed on a newly-developed quantitative systems pharmacology model as part of Physiomics' 'Virtual Tumour' platform.

The model provided a framework that could be applied to optimise the dosing regimens of PARP and ATR inhibitor combinations, thus helping with clinical dosing strategy.

"Being awarded a talk at a high-profile conference such as AACR is a testimony to the scientific quality of our team," said executive chairman and chief executive officer, Dr Jim Millen.

"We are excited to present publicly for the first time our collaborative work with Merck, and we are looking forward to meeting with other attendees of the conference."

At 1116 BST, shares in Physiomics were flat at 2.65p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE